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  Validation of treatment plan quality and dose calculation accuracy is essential for new 
radiotherapy techniques, including volumetric modulated arc therapy (VMAT). VMAT delivers 
intensity modulated radiotherapy treatments while simultaneously rotating the gantry, adding an 
additional level of complexity to both the dose calculation and delivery of VMAT treatments 
compared to static gantry IMRT. The purpose of this project was to compare two VMAT systems, 
Elekta VMAT and Varian RapidArc, to the current standard of care, IMRT, in terms of both treatment 
plan quality and dosimetric delivery accuracy using the Radiological Physics Center (RPC) head and 
neck (H&N) phantom. Clinically relevant treatment plans were created for the phantom using typical 
prescription and dose constraints for Elekta VMAT (planned with Pinnacle3 Smart Arc) and RapidArc 
and IMRT (both planned with Eclipse). The treatment plans were evaluated to determine if they were 
clinically comparable using several dosimetric criteria, including ability to meet dose objectives, hot 
spots, conformity index, and homogeneity index. The planned treatments were delivered to the 
phantom and absolute doses and relative dose distributions were measured with thermoluminescent 
dosimeters (TLDs) and radiochromic film, respectively. The measured and calculated doses of each 
treatment were compared to determine if they were clinically acceptable based upon RPC criteria of 
±7% dose difference and 4 mm distance-to-agreement. Gamma analysis was used to assess dosimetric 
accuracy, as well. All treatment plans were able to meet the dosimetric objectives set by the RPC and 
had similar hot spots in the normal tissue. The Elekta VMAT plan was more homogenous but less 
conformal than the RapidArc and IMRT plans. When comparing the measured and calculated doses, 
all plans met the RPC ±7%/4 mm criteria. The percent of points passing the gamma analysis for each 
v 
 
treatment delivery was acceptable. Treatment plan quality of the Elekta VMAT, RapidArc and IMRT 
treatments were comparable for consistent dose prescriptions and constraints. Additionally, the 
dosimetric accuracy of the Elekta VMAT and RapidArc treatments was verified to be within 
acceptable tolerances. 
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Chapter 1      Introduction 
1.1 Statement of Problem 
 Volume modulated arc therapy (VMAT) is a radiotherapy technique that delivers intensity 
modulated radiation therapy (IMRT) while simultaneously rotating the gantry. VMAT utilizes 
continuous gantry rotation, dynamic beam modulation, and variable dose rate to deliver conformal 
treatments. 
 VMAT evolved from a technique called intensity modulated arc therapy (IMAT), first 
proposed by Cedric Yu as an alternative to tomotherapy (1). IMAT was implemented on an existing 
linear accelerator (linac) and delivered treatments volumetrically, rather than slice by slice. Yu’s 
technique used a multi-leaf collimator (MLC) to shape the beam dynamically while the gantry 
rotated and used multiple overlapping arcs. Each arc delivered one subfield of an intensity modulated 
treatment at each angle. IMAT was similar to the idea of step-and-shoot IMRT, which delivers two-
dimensional intensity distributions from each static gantry position using several subfields. However, 
in IMAT, each subfield at a specific gantry angle would be delivered by separate arcs. The number 
of overlapping arcs depended on the complexity of the intensity distribution desired. Two to five arcs 
were typically required for clinical delivery of IMAT (2). Although Yu first proposed inverse 
planning for IMAT (1), forward planning was used for its actual implementation (2). During 
planning, arcs were approximated as multiple fixed fields at gantry angles separated by 5-10°. The 
plans mostly used three to five arcs and the final dose calculation approximated each arc as fixed 
fields at 10° gantry spacing. 
 Yu recognized that the forward planning techniques he implemented did not fully utilize the 
capabilities of IMAT to deliver conformal treatments. However, there were several challenges to 
developing effective planning and dose calculation techniques. Physical limitations of the linac, 
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including leaf travel speed, dose rate, and gantry rotation speed, complicated planning and affected 
the efficiency of treatments (1-3). Also, determining the optimal gantry spacing to approximate the 
arcs was a trade-off between optimization time, calculation time and accuracy (3). 
 In 2008, Karl Otto proposed the VMAT technique as a solution to the gantry angle sampling 
resolution problem for optimizations and dose calculations (3). A fine sampling improved the dose 
accuracy, but the limited MLC motion between small gantry angles restricted the optimization 
flexibility and increased the time of optimization. A coarser sampling allowed for greater MLC 
motion between gantry angles and, therefore, more freedom in the optimization, but provided a less 
accurate representation of the actual treatment. Otto’s solution was to use an aperture-based 
optimization scheme in which sampling of gantry angle and MLC position was progressively 
increased. It began with a coarse sampling of static gantry positions and MLC aperture shapes and 
ended with a high resolution sampling to accurately model the dose delivered. MLC motion was 
more restricted as the number of samples increases, reducing the flexibility of the optimization, but 
increasing the accuracy of the dose calculation (3). 
 The concept of VMAT introduced by Otto led to the development of commercial VMAT 
treatment planning and delivery techniques, including Elekta VMAT (Elekta AB, Stockholm, 
Sweden), planning with Pinnacle3 SmartArc (Philips Medical, Madison, WI), and Varian 
RapidArc™ with Eclipse treatment planning (Varian Medical Systems, Palo Alto, CA). To deliver 
conformal treatments, these VMAT techniques utilize continuously variable gantry position and 
speed, dose rate, and MLC aperture. 
 The VMAT techniques are marketed as delivering treatment plans equivalent to IMRT in a 
single arc while potentially requiring shorter treatment times and less monitor units (MU) than static 
gantry IMRT. For new techniques it is important for such claims be verified in practice prior to the 
technique’s widespread use. The dose distributions achievable by VMAT techniques should be 
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compared to the standard of care for multiple treatment sites and geometries. Thorough comparisons 
of dose distributions achieved by treatments can help clinicians make decisions about patient 
radiotherapy treatments. If VMAT has plan quality that is equivalent to IMRT but with less MU and 
shorter treatment times, clinicians may choose VMAT to reduce the time a patient spends on the 
table and reduce the leakage radiation a patient receives as a result of fewer MU. 
 The claims about treatment delivery time and MU have been examined by several 
researchers. They have found that the treatment times for VMAT using one or two arcs are 
significantly reduced when compared to both 3D conformal and IMRT treatments (4-7). One study 
found that for head and neck cancers, one and two arc RapidArc treatments had an average reduction 
in MU of 59% from seven field sliding window IMRT (6). In this study, two arc treatments required 
5% more MU than single arc treatments. 
 Plan quality of VMAT treatments has been compared with IMRT in several studies. In a 
planning study of twelve head and neck cancers, RapidArc one and two arc treatments were 
compared to seven field sliding window IMRT and was found to have similar sparing of organ at risk 
(OAR) (6). The homogeneity was best for two arc RapidArc and worst for single arc plans. These 
complex plans had two planning treatment volumes (PTV) treated to different prescriptions, a boost 
PTV and an elective PTV. In the boost PTV, the two arc RapidArc plan was significantly less 
conformal than IMRT. The authors concluded that two arc RapidArc treatment plans were similar to 
the IMRT dose distributions. It is important to note that in this study the versions of RapidArc 
planning used, preclinical Eclipse 8.2.16 and clinical Eclipse 8.2.22, did not allow simultaneous 
optimization of more than one arc, which is supported in current versions (6). 
 A different study compared RapidArc plans to IMRT for four virtual, water equivalent 
phantoms with variations of PTV and OARs (4). They found that RapidArc had better conformity 
and homogeneity and was better able to meet the plan objectives than five and nine field sliding 
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window IMRT. They also concluded that RapidArc plans with two arcs achieved better dose 
distributions than single arc plans (4). 
 Another planning study compared IMRT and Elekta VMAT planned with Pinnacle3 
SmartArc for six prostate and six head and neck patients (7). In this study, they concluded that the 
Elekta VMAT plans were comparable to IMRT in target coverage and critical structure sparing. The 
authors also noted that Elekta VMAT showed promise in complex head and neck cases (7). 
 Plan comparison studies are necessary to help clinicians determine which treatment 
techniques are best for specific treatment sites and geometries. However, the quality of treatment 
plans is subject to the abilities of the planner and the time spent on each plan. Thorough assessment 
of the treatment plans generated by a technique must be conducted by several planners in order to 
make clinicians fully aware of the quality of plans that VMAT techniques can achieve. We need 
more evidence that VMAT plans can be of comparable quality to IMRT, especially for more 
difficult, complex geometries, such as head and neck cancers, where there can be multiple, large 
treatment volumes with nearby critical structures. Additionally, no study has yet compared the 
various VMAT techniques directly to determine if the plan quality varies between the techniques. 
 In addition to studying the quality of dose distributions achieved by VMAT techniques in 
comparison with IMRT, the delivery accuracy of the dose calculated by treatment planning systems 
(TPS) has been investigated in several studies. For a new technique, verifying the accurate delivery 
of dose distributions is an important part of the quality assurance (QA) process prior to the 
technique’s implementation. In one study, the accuracy of RapidArc dose calculation was evaluated 
by a Monte Carlo study of oropharynx radiotherapy (8). In this study, they compared Monte Carlo 
and the treatment planning calculation and determined that the accuracy of RapidArc dose 
calculation was adequate for clinical use when using a 2.5 mm dose grid. 
 Another study evaluated the accuracy of RapidArc dose delivery by patient specific 
verification for nine treatment plans for prostate and head and neck cancers (9). The plans were 
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delivered to a Scandidos Delta4® (Scandidos, Uppsala, Sweden), a cylindrical phantom with arrays 
of diodes, which was calibrated to an ionization chamber. The measured and calculated doses were 
compared using gamma analysis with 3% dose difference and 3 mm distance-to-agreement (DTA) 
criteria. They found that greater than 95% of the points passed in all cases and concluded that dose 
distributions delivered by RapidArc corresponded well with the planned treatments (9).  
 The accuracy of Elekta VMAT dose calculation for prostate and lung cancer plans was 
evaluated by measurements in a different study (5). One lung plan was delivered to a Delta4 
phantom. Two prostate plans were delivered to a stack of Solid Water® (Gammex, Inc., Middleton, 
WI) and the dose was measured by an ionization chamber. One of the prostate plans was also 
delivered to the Delta4 phantom. For all tests, gamma analysis was used to evaluate dose delivery 
accuracy with 3% dose difference and 3 mm DTA criteria. For all treatments delivered to the Delta4 
phantom, greater than 95% of the points passed. The dose measured by the ionization chamber in the 
Solid Water stack was less than 3% different from the calculated dose for both prostate treatments. 
The authors concluded that the measured and calculated dose distributions agreed well (5). 
 In another study the dose distributions of RapidArc plans for head and neck radiotherapy 
were measured in a QA phantom with GAFCHROMIC® EBT (International Specialty Products, 
Wayne, NJ) films in several coronal planes (6). The dose verification was evaluated using gamma 
analysis with 3% dose difference and 2 mm DTA criteria. For plans with one and two arcs, the 
average passing rate was greater than 97% and greater than 99%, respectively. In this study, one case 
compared single and two arc plans to IMRT and found that the two arc plan was the best with 99.1% 
of points passing. In comparison, IMRT had 96.4% passing. The authors noted that although EBT 
film provides good spatial resolution (0.3 mm), it is a less accurate and stable method of dosimetry 
than ionization chamber arrays. In conclusion, they determined that RapidArc treatments were 
accurately delivered (6). 
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 The accurate delivery of calculated dose distributions was evaluated in another study for six 
prostate and six head and neck treatment plans created using Pinnacle3 SmartArc for Elekta VMAT 
(7). The MatriXX™ 2D ionization chamber array in a MultiCube™ phantom (IBA Dosimetry Inc., 
Memphis, TN) was used for the plan QA. The gamma analysis was used to evaluate accuracy using a 
3% dose difference and 3 mm DTA criteria. For the prostate and head and neck plans, the average 
passing rate was 98.9% and 98.3%, respectively. In comparison, the IMRT passing rates were 98.5% 
and 97.7%. The authors concluded that Elekta VMAT accurately delivered the planned treatments 
(7). 
 All of the dose delivery verifications have been similar to the type of dose verification 
employed for patient specific QA. Until now, no study has been conducted that uses a standardized 
and recognized method to verify that calculated doses are accurately delivered. Dose verification is 
necessary to assure physicists and clinicians of the accuracy with which patient treatments are 
delivered. This is especially important for complex treatments, such as in head and neck cancers, 
where conformal treatments need substantial intensity modulation to generate steep dose gradients. 
 In this project, we evaluated the plan quality of two VMAT techniques, Elekta VMAT 
planned with Pinnacle3 SmartArc and Varian RapidArc, for a complex head and neck phantom 
radiotherapy treatment and compared the treatment plans to the current standard of care, IMRT. 
Additionally, the delivery accuracy of the calculated doses was evaluated using the protocol 
established by the Radiological Physics Center (RPC) for head and neck IMRT. This standardized 
protocol is used by the Radiation Therapy Oncology Group to credential institutions participating in 
clinical trials. 
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1.2 The Radiological Physics Center and Anthropomorphic QA Phantoms 
 The Radiological Physics Center (RPC) was founded in 1968 as a National Cancer Institute 
(NCI) funded group with the mission to ensure that “institutions participating in clinical trials deliver 
prescribed radiation doses that are clinically comparable and consistent” (10). In multi-clinic studies, 
it is essential that radiation therapies delivered across all participating clinics are similar and that 
results are not skewed because of dosimetric differences between clinics. The RPC monitors the 
participating institutions by performing quality reviews through its on-site dosimetry review visits 
and off-site remote auditing techniques. The off-site auditing program includes: 
• A mailable TLD program to verify machine output 
• Comparison of the institutions’ dosimetry data with RPC standard dosimetry data 
• Evaluation of reference or actual patient calculations to verify treatment planning 
algorithms 
• Review of the institutions’ written QA procedures and records 
• Mailed anthropomorphic phantoms to verify tumor dose delivery for special 
advanced treatment techniques such as IMRT, stereotactic radiosurgery, etc. 
• Credentialing of institutions for participation in specific protocols 
• Retrospective review of treatment records for patients entered into cooperative 
clinical trials. 
 The purpose of the anthropomorphic phantom audit process is to assess an institution’s 
ability to image the phantom, develop a specific treatment plan, and deliver the dose according to 
specific protocol guidelines or instructions. The phantom is treated as if it were an actual patient. The 
RPC currently has five anthropomorphic phantoms, a stereotactic radiosurgery head phantom, an 
IMRT head-and-neck phantom, a thorax phantom, a liver phantom, and a pelvic phantom. The basic 
design of each phantom is similar and consists of an outer plastic shell in the appropriate anatomical 
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shape. The shell is filled with water to represent soft tissue and has a compartment that houses the 
imageable targets and organs at risk where dosimeters are located. Radiochromic film and TLD are 
used for relative and absolute dose measurements, respectively. The films are located in two major 
planes and the TLD is used to normalize the film readings as well as measure the dose at a point. 
Once the phantom has been irradiated, it is returned to the RPC where the dosimeters are analyzed 
and compared to the institution’s treatment planning system’s dose calculations. 
 These phantoms are mailed to institutions that participate in cooperative clinical trials as a 
means to remotely evaluate their ability to plan and deliver dose within specific protocol criteria for 
field localization and dose delivery to targets and critical structures. Some radiation therapy clinics 
may be replacing IMRT with VMAT for certain treatment sites. In order to allow VMAT users in 
RTOG clinical trials involving IMRT, the RPC must ensure that VMAT treatments can deliver 
clinically comparable treatments to IMRT. 
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1.3 Hypothesis and Specific Aims 
 We hypothesized that VMAT techniques generate treatment plans of comparable quality to 
IMRT and accurately deliver the calculated dose for complex head and neck treatments. 
 
 The hypothesis was tested by the following specific aims: 
1) We created clinically relevant treatment plans for the RPC IMRT head and neck phantom 
from typical prescription and dose constraints for 1) Elekta VMAT planned with Pinnacle3 
SmartArc, 2) Varian RapidArc and 3) 6 MV IMRT. 
2) We evaluated the plan quality of the two VMAT and one IMRT head and neck treatment 
plans to determine if they were clinically comparable. 
3) We delivered the three planned treatments to the head and neck phantom and measured the 
dose distribution from each. 
4) We compared the measured and calculated doses using clinically acceptable criteria of ±5% 
dose difference and 3 mm DTA. 
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Chapter 2      Methods and Materials 
2.1 VMAT Techniques Evaluated in This Study 
2.1.1 Elekta VMAT Planned with Pinnacle SmartArc 
 The first VMAT technique evaluated in this study was a treatment plan generated using the 
SmartArc module in Pinnacle version 9 (Philips Medical, Madison, WI) and delivered using an 
Elekta Synergy linac (Elekta AB, Stockholm, Sweden). Pinnacle’s VMAT treatment planning is 
based on work  by Bzdusek, et al (11). It uses an inverse-planning approach based on dose-volume 
objectives that generates treatment plans with dynamic MLC and variable dose rate and gantry 
rotation speeds. The optimization takes into account the machine constraints in order to develop a 
deliverable plan. 
 First, the user sets up the arcs for optimization and inputs parameters such as arc length, 
collimator and couch angle, maximum arc delivery time, and final gantry spacing. Additionally, the 
TPS can generate additional arcs to be optimized simultaneously using the same parameters as the 
initial arc, but with opposite rotation direction. This is known as the dual arc feature. The initial 
optimization step generates fluence maps at a coarse resolution of 24° around each arc. Once this 
optimization has converged, each fluence map is converted to two to four MLC segments, depending 
on the extent of intensity modulation. Of these segments, the two with the most open leaf pairs are 
kept per initial angle. These segments are redistributed evenly around the arc. The MLC segments 
are now located every 8°. If the dual arc feature is employed, five MLC segments are generated per 
initial angle and two are kept per arc. In this case, the MLC segments are distributed in a manner that 
reduces leaf travel in each arc. 
 The next optimization step uses Pinnacle’s Direct Machine Parameter Optimization (DMPO) 
on the existing control points. The MU and leaf positions for each control point and arc delivery time 
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are all variables included in the optimization. These variables are limited by the machine and user 
specified constraints, such as maximum and minimum dose rate and gantry rotation speed, maximum 
leaf speed, and maximum arc delivery time. 
 To improve the accuracy of the dose calculation during DMPO, the arc sampling resolution 
is reduced to the final gantry spacing by linearly interpolating leaf segments between the existing 
control points. The typical final gantry spacing is 4°, resulting in 91 control points. The interpolated 
control points are only used to improve the dose calculation accuracy and are not included in the 
DMPO. During optimization the dose is calculated using the Singular Value Decomposition (SVD) 
dose engine, a fast pencil beam algorithm that accounts for tissue heterogeneities in the primary 
beam. Once the machine parameters have been optimized, the jaw positions are determined. 
 The final dose is calculated using a convolution/superposition algorithm, either Adaptive 
Convolve or Collapsed-Cone Convolution, and each arc is approximated as 91 control points, 
assuming the typical final gantry spacing of 4° was selected by the user. In this study, we used the 
Adaptive Convolve dose calculation algorithm in Pinnacle. In flat areas, the dose grid is sampled at 
every fourth point and the dose in between is interpolated. The algorithm will switch to a full 
sampling if the dose grid cannot be interpolated accurately. The convolution/superposition 
algorithms in Pinnacle model the primary energy fluence and the head scatter and adjust for 
heterogeneities.  
 The control point information of the treatment plan, including MU and MLC aperture, is 
then transferred to the treatment machine. The control system of the linac, an Elekta Synergy in our 
study, determines the dose rate and gantry speed based on the plan information. 
2.1.2 Varian RapidArc 
 The second VMAT technique evaluated in this study was RapidArc, which was planned in 
Eclipse version 8.6 and delivered on a Varian Clinac iX linac (Varian Medical Systems, Palo Alto, 
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CA). Varian developed RapidArc based on the work of Otto and his novel optimization scheme, 
which Varian has termed their Progressive Resolution Optimizer (PRO) algorithm (3). Like 
Pinnacle’s algorithm, it uses dose-volume objectives for an inverse-planning approach. The final 
plans have dynamic MLC, variable dose rate and variable gantry rotation speeds. The final dose is 
calculated using the Anisotropic Analytical Algorithm (AAA). 
 After the user has setup up the basic arc parameters, including arc length and collimator 
angle, the PRO begins optimizing each arc by modeling it as a small number of equally-spaced static 
control points with the same initial dose rate and MLC aperture conforming to the target shape. 
Then, the MLC aperture and dose rates are varied iteratively and the dose is calculated at each 
iteration point. The dose is calculated by first determining the fluence from the MLC aperture and 
dose rate and then converting it to dose using Eclipse’s Multi-Resolution Dose Calculation (MRDC) 
algorithm, a fast convolution superposition algorithm that corrects for heterogeneities for the primary 
dose component. A cost function based on the dose-volume objectives set is used to determine if 
each variation should be kept. The algorithm then steps through various stages of resolution in which 
it adds control points to each arc progressively and continues to optimize all MLC shapes and dose 
rates. The final resolution level finishes with 177 control points per arc, which leads to control points 
approximately every 2° for a 360° arc. 
 Once the optimization has finished, Eclipse uses the AAA to calculate dose, with each arc 
approximated as 177 static control points. AAA models the treatment beam as beamlets of multiple 
sources: the primary photons generated in head and secondary sources scattered from the linac head, 
including the extra-focal photons and the contaminating electrons. The AAA dose engine also 
accounts for tissue heterogeneities. 
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2.2 The RPC Anthropomorphic IMRT Head and Neck Phantom 
 The phantom used throughout this study was an anthropomorphic head and neck phantom 
designed and constructed by the RPC for credentialing of institutions participating in RTOG head 
and neck protocols involving IMRT. The phantom, shown in Figure 2-1, was designed to mimic the 
geometry of this treatment site and to hold radiation dosimeters for measuring the dose delivered to 
the phantom. The phantom was constructed of materials that are tissue-equivalent. 
 The phantom consists of a plastic outer shell shaped like a human head and neck. The water-
tight shell is hollow except for a polystyrene insert and can be filled with water to simulate the 
human tissue surrounding the insert (12). There are 
plugs in the bottom of the phantom through which water 
can be filled and drained from the phantom. 
 The removable dosimetry insert, seen next to the 
phantom in Figure 2-1, contains the treatment volumes 
and places to insert radiation dosimeters. It is 13 cm in 
height, 10.5 cm wide, and 7.5 cm long (12). The 
dosimetry insert has two halves that can be separated for 
the insertion and removal of dosimeters. Figure 2-2 
shows the superior half of the insert next to an axial CT image of a cross-section of the insert. The 
structures simulated in the insert are indicated in Figure 2-2 and include two solid water PTVs and an 
acrylic OAR representing the spinal cord. The primary PTV represents an orophanryngeal tumor and 
the secondary PTV represents the peripheral nodes. The densities of the materials in the insert are 
sufficiently different so they are readily visualized on CT images without having a significant effect 
on the treatment fields. The difference in atomic number of the materials is also insignificant for 
treatment. The secondary PTV and OAR are cylinders with their axes in the superior-inferior 
 
Figure 2-1 RPC IMRT head and neck 
phantom with dosimetry insert removed 
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direction and the dimensions shown in Table 2-1 (12). The primary PTV is in the shape of a cylinder 
oriented in the same direction as the other structures, but with a portion cut out on its posterior side 
where it wraps around the abutting OAR volume. 
 As shown in Figure 2-2, the inner side of each insert half has four holes drilled for holding 
thermoluminescent dosimeter (TLD) capsules to measure absolute dose in eight locations. The TLD 
capsules are placed in pairs, with one TLD in the superior half of the insert and another in the same 
location in the inferior half. There are two pairs of TLD in the primary PTV offset from the center (a 
posterior and an anterior pair) and a pair in the center of both the secondary PTV and the OAR. 
 There are three radiochromic films placed in the insert to measure the dose distribution in the 
axial and sagittal planes. There is one film in the axial plane where the two halves of the insert meet 
and two films in the sagittal plane bisecting the primary PTV, one in each half of the insert. The gap 
 
Figure 2-2 Picture (left) and axial CT image (right) of phantom insert with the anterior edge on top 
Table 2-1 Dimensions of structures in the phantom insert 
Structure Diameter (cm) Length (cm) 
Primary PTV 4 5 
Secondary PTV 2 5 
Organ at risk 1 13 
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for the sagittal film in the superior half of the insert is shown in Figure 2-2. The sagittal films have a 
cutout where the TLDs in the OAR are located. 
 On the axial face of the inferior insert, pins are located in three of the corners to poke holes 
in the film. Additionally, there are five tiny holes drilled in the outer left side of the insert through 
which a small tool can be inserted to pierce the sagittal films. The holes left by piercing the film are 
useful for registering the film to the treatment plan later. More details are provided in section 2.5.4 
Film, Plan, and Phantom Registration for more details about film and treatment plan registration. 
 
2.3 Treatment Planning 
 To determine if the two VMAT techniques evaluated in this study were clinically 
comparable to IMRT for head and neck radiotherapy, we created clinically relevant treatment plans 
for the RPC IMRT head and neck phantom from common prescription and dose constraints for each 
technique evaluated in this study: Elekta VMAT planned with Pinnacle3 SmartArc, Varian RapidArc 
and 6 MV IMRT. 
2.3.1 Phantom Imaging 
 We performed a CT simulation of the phantom to acquire images of the phantom for 
treatment planning. We positioned the phantom supine and “head-first” on the table and used the 
lasers to place external radiopaque markers on the phantom. Next, we placed masking tape where the 
lasers crossed on the left and right sides and face of the phantom and drew crosshairs to mark the 
treatment isocenter. We then took a scout image of the phantom and set the scan extent to include 
enough margin superior and inferior of the phantom insert to include the effects of scatter in the dose 
calculation. 
 For the Elekta VMAT treatments, we simulated the phantom using a GE LightSpeed® RT 
16-slice CT scanner (GE Healthcare, Waukesha, WI). The CT simulation used the parameters 
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specified by the protocol for a stereotactic head and neck patient at Mary Bird Perkins Cancer 
Center. The protocol generated 1.25 mm thick images. CT data were imported into the Pinnacle3 
TPS for the Elekta VMAT treatment planning. 
 For the IMRT and RapidArc treatments, we simulated the phantom using a Philips Brilliance 
64-slice CT scanner (Philips Healthcare, Andover, MA) and the AcQSim workstation. The CT 
simulation used the parameters specified by the MD Anderson protocol for a head and neck patient, 
but with the slice thickness reduced from 2.5 mm to 1.5 mm to better visualize the TLDs in the 
phantom. The CT data for the IMRT and RapidArc treatments were imported into the Eclipse TPS 
for planning. 
2.3.2 Dose Prescription and Constraints 
 The same treatment planning objectives were used for all treatment plans and were based on 
RPC specifications. These criteria were derived from a head and neck prescription for the RTOG 
protocol 0022: 66 Gy to the primary PTV (the tumor) and 54 Gy to the secondary PTV (the 
peripheral node). However, these high doses are out of the useful range for GafChromic® EBT2 film 
and have been scaled down by a factor of ten for the RPC phantom test case resulting in a primary 
prescribed dose of 6.6 Gy and secondary dose 
of 5.4 Gy. At least 95% of the primary PTV 
volume must receive its prescription dose (D95% 
≥ 6.6 Gy). Also, 95% of the secondary PTV 
must receive at least 5.4 Gy (D95% ≥ 5.4 Gy). 
The OAR simulates the spinal cord, so it was 
not allowed to receive more than 4.5 Gy, one-
tenth of the 45 Gy dose limit for the spine. 
Additional treatment planning criteria included minimizing the hot spots and that 99% of each target 
Table 2-2 Dosimetric criteria set by the RPC and 
used for planning all treatments 
Structure Dosimetric Criteria 
Primary PTV 
D95% ≥ 6.60 Gy 
D99% ≥ 6.14 Gy 
Secondary PTV 
D95% ≥ 5.40 Gy 
D99% ≥ 5.03 Gy 
Normal tissue max dose ≤ 7.26 Gy 
Organ at risk max dose < 4.50 Gy 
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volumes must receive more than 93% of that target’s 
prescription dose. These criteria are summarized in 
Table 2-2. 
2.3.3 Volume Delineation 
 Using the image segmentation tools in each 
corresponding TPS, we contoured the two PTVs and the 
OAR without any expansions (see Figure 2-3). A total 
body structure was generated, automatically in Eclipse 
and manually in Pinnacle. We created a normal tissue 
structure by subtracting the two PTV volumes from the total body structure. We also contoured each 
of the eight TLD. In the Eclipse TPS, the TLD had to be converted to high resolution segments 
before adequate contouring was possible. 
2.3.4 Treatment Plans 
 In the TPS, we localized the plans to the radiopaque external fiducials indicating the 
simulation isocenter, which can be seen on the CT image shown in Figure 2-3. We placed the 
treatment isocenter at the geometric center of the two PTV structures. To do this, we made a single 
structure from both the primary and secondary PTVs. We determined the couch shifts necessary to 
move from the simulation isocenter to the 
treatment isocenter. 
 The treatment couch for each of the 
three treatment plans was defined as follows. 
For the SmartArc plan, we removed the 
simulation couch. For the RapidArc and IMRT 
 
Figure 2-3 Contoured structures in 
Eclipse: primary PTV (blue), secondary 
PTV (yellow), and OAR (red) 
 
Figure 2-4 Couch structure (purple) inserted for 
the IMRT and RapidArc plans 
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plans, we added the Exact® couch top with flat panel structure with the rails in the out position. This 
couch is shown in Figure 2-4 and represents the actual linac couch on which the corresponding 
treatments were delivered.  
 The treatments were planned based on the typical clinical head and neck radiotherapy 
parameters of the institution in which the treatments were delivered. Both VMAT plans consisted of 
two full coplanar 6 MV arcs. The Elekta VMAT plan (planned with Pinnacle SmartArc) used a 45° 
collimator for both arcs and the RapidArc plan had a collimator offset of ±15° (345° and 15°). The 
IMRT plan used nine coplanar, equally-spaced 6 MV beams (200°, 240°, 280°, 320°, 0°, 40°, 80°, 
and 160° seen in Figure 2-5) and a 0° collimator was set. The couch was set at 0° for all plans. 
 We set the final gantry spacing of the Pinnacle SmartArc plan to 4°. All plans were initially 
optimized until the planning criteria set by the RPC were met. More optimization attempts were 
made to improve the homogeneity and conformity of the dose distributions. We attempted to reduce 
 
Figure 2-5 Beam angles entering body in 3D view of nine field IMRT treatment plan 
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the hot spots in the PTVs and make the dose in these structures as homogenous as possible. We 
created additional structures, such as volume expansions, rings and avoidance structures, to conform 
the prescription dose to the PTVs as much as possible. 
 The final dose for the SmartArc plan was calculated with the Adaptive Convolve dose 
engine. The RapidArc and IMRT plans were calculated with the AAA dose engine. All plans were 
calculated using a 4 mm calculation grid and were normalized to approximately 95% of the primary 
PTV receiving 6.6 Gy. The Elekta VMAT, RapidArc, and IMRT plans had a total of 1491, 2494, and 
2274 MU, respectively. The total number of MU for each arc of an individual delivery of the Elekta 
VMAT and RapidArc plans were high and the treatments were splits into three and two fractions, 
respectively. The dose per fraction was reduced correspondingly to achieve the full 6.6 Gy 
prescription. The final treatments were delivered in three fractions of 2.2 Gy for Elekta VMAT and 
two fractions of 3.3 Gy for RapidArc. 
 
2.4 Treatment Plan Quality Comparison 
 We evaluated the plan quality of the two VMAT and one IMRT head and neck treatment 
plans to determine if they were clinically comparable. First, we evaluated each plan’s ability to 
achieve the dose objectives set by the RPC, outlined in Table 2-2. To qualitatively evaluate the 
quality of each treatment plan, we generated and examined dose-volume histograms (DVH). 
 To compare the plans on their ability to minimize hot spots and to keep doses to normal 
tissues low we recorded the maximum doses in each PTV, the OAR, and normal tissue. The 
maximum dose was taken as the dose to the hottest 0.1 cc from the DVH. Additionally, the 
percentage of the secondary PTV receiving its prescription dose, its PTV coverage, was compared 
for all plans. The primary PTV coverage was not compared because the plans were normalized to the 
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prescription dose covering 95% of the primary PTV. The secondary PTV coverage indicated the 
plans ability to give adequate dose to a secondary volume while maintaining primary PTV coverage. 
 We quantified how well the prescription dose conformed to the primary PTV using the 
conformity index (CI) expressed in equation 2-1. The CI evaluated a plan’s ability to spare normal 
tissue from the high doses delivered to treatment volume. In equation 2-1, Vprescrip was the total 
volume of tissue receiving the prescription dose, 6.6 Gy. VPTV was the volume of the primary PTV 
structure. 
PTV
prescrip
V
V
CI =       Eq. 2-1 
 Since optimal plans have uniform doses in their treatment volumes, the homogeneity of each 
PTV was evaluated. We used the homogeneity index (HI), described in equation 2-2 below, to 
characterize the homogeneity. D5% was the dose delivered to the hottest 5% of PTV structure and 
D95% was the minimum dose received by 95% of the PTV structure, both taken from the plan’s DVH.  
%95
%5
D
DHI =       Eq. 2-2 
 
2.5 Dosimetric Accuracy Evaluation 
 To determine if the dosimetric accuracy of the VMAT techniques was clinically acceptable, 
we delivered each of the three planned treatments to the RPC IMRT head and neck phantom and 
measured the dose distribution with TLDs and radiochromic film. 
2.5.1 Phantom Irradiation 
 We delivered the Elekta VMAT plan on an Elekta Synergy® linac at Mary Bird Perkins 
Cancer Center in Baton Rouge, LA. The Synergy was equipped with an MLCi2 which had 10 mm 
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leaf width and forty leaves per bank. The linac was calibrated following the TG-51 protocol to 1 
cGy/MU in muscle at dmax under reference conditions of 100 cm SSD and 10 cm by 10 cm field size. 
 We delivered the RapidArc and IMRT plans on a Varian Clinac iX linac. The MLC system 
was the Varian Millennium 120 which had sixty leaves per bank. The central 40 leaves were 5 mm in 
width and the peripheral leaves were 10 mm in width. The linac was calibrated following the TG-51 
protocol to 1 cGy/MU in muscle at dmax under reference conditions of 100 cm SSD and 10 cm by 10 
cm field size. 
 Prior to the delivery, we measured the machine output for 6 MV x-rays using the monthly 
QA protocol of the linac’s institution. After the machine output was verified, we positioned the 
phantom on the treatment table in the same manner as the simulation: head-first supine, and lined up 
to the simulation isocenter indicated by the initial crosshair marks (see Figure 2-6). Then, we shifted 
the couch to the treatment isocenter and drew new crosshairs on the top and sides of the phantom.  
 We delivered each treatment as 
specified by its treatment plan and delivered all 
fractions. Each irradiation of the Elekta VMAT 
plan and RapidArc plan involved delivering 
three and two fractions, respectively (refer to 
section 2.3.4 Treatment Plans for explanation). 
The treatment deliveries and measurements 
were repeated three separate times. We loaded 
new TLD and radiochromic films into the 
phantom prior to each irradiation. Between 
each irradiation, we had to remove the insert to 
unload the previous treatment’s dosimeters and 
 
Figure 2-6 Photograph of phantom on treatment 
table of the Varian Clinac iX linear accelerator 
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replace with new ones. The setup was confirmed prior to each irradiation and the phantom adjusted 
as necessary to align the phantom to the treatment isocenter. 
 We performed an additional output check following a standardized RPC protocol that 
involves irradiating two TLDs in 4.4 cm by 4.4 cm square blocks of PMMA under conditions 
specified by the RPC. These blocks, known as mini-phantoms, were 3 cm tall with the TLDs located 
in the middle at 1.5 cm depth. The field size was 10 cm by 10 cm and the source-to-surface distance 
(SSD) was set to 100 cm to the top of the block. 300 MU of 6 MV photons were delivered to the 
TLDs, which were at the dmax for 6 
MV. The TLD block and setup are 
shown in Figure 2-7.  
 The doses to the TLDs were 
subsequently read-out by the RPC 
and corrections were applied to 
determine the machine output. The 
purpose of this check was to 
compare the machine output with 
the nominal dose for 300 MU under 
reference conditions. We used this value later to correct our measurements for machine output 
variations from the nominal output used to calculate dose (see section 2.5.3 Absolute Point Dose 
Analysis). 
 All plans were delivered using the record and verify system, Mosaiq, and treated in QA 
mode. 
 
Figure 2-7 Setup of the RPC machine output check involving 
irradiating two TLD in a Lucite block mini-phantom 
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2.5.2 Dosimeters 
 TLD and radiochromic film are radiation dosimeters that are used extensively by the RPC in 
their credentialing process. The dosimeters measure radiation dose passively and are ideal for remote 
audits where the phantom is mailed to an institution, irradiated, and then mailed back to the RPC for 
analysis. In this study, TLD and radiochromic film were used to measure absolute point doses and 
relative dose distributions, respectively. 
2.5.2.1 Thermoluminescent Dosimetry 
 Thermoluminescent (TL) dosimetry is based upon the thermoluminescence process in which 
light is emitted from a material upon heating. These materials, known as TL phosphors, are crystal 
structures that contain imperfections, known as traps. These traps hold electrons or their holes in an 
electric potential well. When the crystal is heated, these electrons and holes can recombine at 
luminescence centers. When this occurs, a light photon is released. The intensity of this light 
released can be measured. 
 Some of these TL phosphors can perform as dosimeters if the energy deposited by radiation 
causes an ionization event that raises electrons to the traps. If the number of electron-hole pairs in 
traps is approximately proportional to the energy deposited by radiation, then the radiation dose 
received by the crystal material can be determined from the intensity of light released. 
 The RPC uses lithium fluoride powder doped with magnesium and titanium impurities to 
provide traps, a TL phosphor, as the sensitive material in their TLD. This material is also known as 
TLD-100. The sensitive part of the dosimeter is housed in a high-impact polystyrene cylindrical 
capsule, 15 mm tall and 4 mm in diameter. There are two separate packets of powder in each 
capsule, about 20 mg each, that yield two measurements. 
 The radiation dose received by the powder is determined by heating each packet of powder 
individually and measuring the amount of light emitted by a photomultiplier tube. The reading is 
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adjusted by several correction factors to obtain absorbed dose to muscle, D, as seen in Equation 2-3 
below.  
FLESMD ××××=     Eq. 2-3 
 M is the TL response per mass of powder measured. S is the system calibration factor, 
absorbed dose per system response, which is found by measuring the TL response of TLD irradiated 
to known doses by Co-60 under standard conditions. E is an energy correction that is applied since 
the TL material response varies with energy slightly differently than tissue. Also, L is a linearity 
correction factor that is applied because the TL response is not exactly linear with dose and becomes 
supra-linear at higher doses. Lastly, F, a fading correction factor is applied that is dependent on the 
time elapsed from the irradiation to the reading. The reading fades at a rate that decreases 
exponentially with time because the trapped electrons and holes are not completely stable. The 
fading rate is dependent on the depth of the trap (energy required to excite electron sufficiently to 
enable recombination). Shallower, more unstable traps fade faster. By about ten days post irradiation, 
the fading becomes relatively constant (13). Therefore, the RPC waits a minimum ten days to 
measure the TL response to allow the most unstable traps to recombine and reduce the uncertainty of 
the measurement due to uncertainty of the exact time elapsed since irradiation. 
 The RPC determines the energy response, dose linearity, and fading corrections for each 
batch of TLD they use. A single batch was used for this study and corresponding corrections were 
applied. The TLD were all read at least 14 days post-irradiation. This TLD system has been shown to 
agree with ionization chamber measurements within ±4% at a 90% confidence level (13). The 
precision of the TLD measurement system is 3%. 
2.5.2.2 Radiochromic Film Dosimetry 
 Radiochromic film is a radiation dosimeter that measures planar radiation dose distributions. 
Unlike radiographic film, it is self-developing and requires no processing post-irradiation. It has 
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good spatial resolution (< 0.1 mm) which makes it ideal for measuring high dose gradients (14). The 
particular radiochromic film used in this study was GafChromic® EBT2 (International Specialty 
Products, Wayne, NJ) which is designed for use in external beam radiation therapy applications. 
 EBT2 film is nearly tissue equivalent (Zeff = 6.84 according to the manufacturer) and has low 
energy-dependence in the energy range of therapeutic radiation and its scatter. Its response reported 
by the manufacturer is about 10% different at 60 keV from 6 MV. A more recent study has found 
that the response varies only about 4.5% from energies of 75 kVp to 18 MeV (14). EBT2 is designed 
for measurement of doses ranging from 1 cGy to 40 Gy. 
 The active component of the film is a 30 micron thick layer of material that develops a blue 
polymer upon exposure to ionizing radiation. The active layer also contains a yellow dye that 
reduces the light sensitivity of the film and causes the film to appear to turn dark green with 
exposure. Irradiation causes the film to absorb light at 636 nm and 585 nm peaks. The reduced 
transmission of light, the optical density (OD), is related to the dose received. 
 Three films were cut from a template for each phantom irradiation. The two sagittal films, 
superior and inferior, were cut to fit into the slots in the insert and had a cutout for the OAR TLD. 
The axial film was cut to the approximate shape of the insert and sandwiched between the two halves 
of the insert. The films were marked along the edges to maintain the correct orientation. 
 The recommendations by AAPM Task Group 55 for radiochromic film handling and 
dosimetry were followed in this study (15). We read all films at least 10 days post-irradiation to 
allow the film to fully develop and reduce uncertainties caused by the density increase, which is 
proportional to the logarithm of time. The films were kept in consistent conditions of low humidity 
and room temperature and were stored in dark, light-blocking envelops. An un-exposed piece of film 
was stored with each set of film to measure background radiation. 
 We measured the OD distribution of the EBT2 film using a transmission densitometer, the 
CCD100 Microdensitometer (Photoelectron Corporation, Lexington, MA). This system consisted of 
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placing the films on a light box with light-emitting diodes (LED) and measuring the light transmitted 
through the films with a charge-coupled device (CCD) camera. The LEDs emissions were centered 
at 665 nm, which is close to the primary absorption peak of irradiated EBT2 film. The system was 
enclosed in a light-tight closet to prevent outside light contaminating the measurement. We set the 
camera to the optimal focal distance from the film, based on the size of area to be measured, 150 mm 
by 150 mm in the center of the densitometer, and subsequently checked the focus. Outside of this 
focal area, we covered the densitometer with a black mask to block the light. The resolution of the 
CCD camera was 512 by 512 pixels, resulting in pixel sizes of about 0.3 mm. 
 Next we imaged a blank piece of film from the same batch covering the entire imaging area. 
This image was stored as a ‘flat field’ to correct for scanner variations in the subsequent readings. 
Then we set a spatial calibration by imaging a 10 mm by 10 mm grid. After the scanner was 
calibrated, we measured the optical densities of the experimental films, maintaining the same film 
orientation during reading. We imaged the axial film by itself and the two sagittal films together, 
allowing for a small separation between the superior and inferior films. The measurements were 
saved as .FIT files. 
 To generate a dose response curve that correlated OD to radiation dose for our specific batch 
of EBT2 film, we performed a calibration of the film batch. We cut nine 3 cm by 3 cm squares of 
film and marked them to maintain their orientation. All film squares were placed on the center of 9 
cm slabs of solid water on a linac table and covered with a 1.5 cm slab of solid water. The pieces 
were oriented approximately 1 cm apart. We set a 100 cm SSD to the top of the solid water stack and 
centered it in a 35 cm by 35 cm field. We then irradiated the film squares with 6 MV photons at the 
dmax depth, 1.5 cm. We delivered a specified number of MU, removed a single square of film, re-
positioned the setup, and delivered another specified number of MU until all nine squares of film had 
been irradiated to a different total number of MU. The total number of MU delivered to each square 
of film can be seen below in Table 2-3. The dose delivered to each square of film was calculated by 
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multiplying the total delivered MU by the output factor for a 35 cm by 35 cm field, 1.095, and are 
also shown in Table 2-3. The film squares were exposed to doses ranging from 0.55 Gy to 14.78 Gy. 
 
 We imaged each square of film using the same method described above and measured the 
OD over a region of interest in the center of each square three times. A background square of film 
that was stored with the calibration film squares was also measured and the value subtracted from the 
average OD of each square. We plotted the net optical densities against the calculated dose delivered 
and fit a third-order polynomial to the data (see Figure 2-8). We used the equation of the fit, equation 
2-4, to convert the OD of our experimental films, x, to dose, D, in Gy. The OD of the corresponding 
background film was measured and subtracted from the OD of the experimental films before 
converting to dose. 
xxxD 0476.7793.20289.38 23 +−=     Eq. 2-4 
Table 2-3 Irradiation of EBT2 film 
batch to generate a dose response 
curve for film calibration 
square # Total MU 
Dose 
(Gy) 
1 50 0.55 
2 150 1.64 
3 250 2.74 
4 350 3.83 
5 550 6.02 
6 750 8.21 
7 950 10.40 
8 1150 12.59 
9 1350 14.78 
28 
 
 
 
 
2.5.3 Absolute Point Dose Analysis 
 The absolute dose delivered to each of the eight TLDs in the phantom insert was measured 
using the RPC method described in 2.5.2.1  
Thermoluminescent Dosimetry. The output of the machine was determined from the pairs of TLD 
irradiated in the mini-phantoms during the same sessions as the head and neck phantom irradiations. 
To ensure a true comparison of the calculated dose to delivered dose without the effects of machine 
output variation, we normalized the measured dose to the measured machine output. We then 
compared these corrected measured doses to the doses predicted by the TPS, which were the mean 
doses in the TLD structures recorded from the TPS. We found the ratio of the corrected measured 
dose to the TPS calculated dose for each TLD site. To comply with RPC standards, the measured 
point doses of the primary PTV and secondary PTV must be within ±7% of the calculated dose; the 
ratio must be within 0.93 to 1.07.  
 
Figure 2-8 Dose response curve for the batch of EBT2 film used in this study 
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2.5.4 Film, Plan, and Phantom Registration 
 To facilitate comparing measured dose distributions to the calculation of the treatment 
planning systems, the films and treatment plan data had to be registered to a single coordinate 
system. We exported the plans, CT images, and dose distributions from Pinnacle and Eclipse in the 
DICOM-RT format. We then imported them into the Computational Environment for Radiotherapy 
Research (CERR) (J.O. Deasy and Washington University, St. Louis, MO). This software was 
developed for the MATLAB® language (The MathWorks, Inc., Natick, MA) to view and analyze 
treatment plans in a standard format. In this software, we were able to register the treatment plan to 
the actual phantom coordinates by selecting specified points on the treatment planning CT images 
that correspond to known locations in the phantom. 
 In an additional program developed for MATLAB, called rpcfilm, we opened the .FIT files 
containing the OD information of the films. We used the holes pierced in the film, which were 
visible in the film images, to register the film to the phantom coordinates of the actual pins and 
converted from OD using the dose response curve we generated (see Figure 2-8). We accounted for 
the OD of the background film piece. 
 To allow a comparison of absolute dose, the film dose was normalized to the corresponding 
dose measured by the TLDs in the primary PTV. In several locations, the ratio of the TLD-measured 
dose to the film-measured dose was determined. For the axial film, the average of the superior and 
inferior TLD doses were used to determined the ratios of dose at the locations on the film 
corresponding to the sets of anterior and posterior TLD. For the sagittal films, we determined the 
ratios of the locations corresponding to all four TLDs in the primary PTV: anterior superior, anterior 
inferior, posterior superior and posterior inferior. For each film plane measurement, axial or sagittal, 
we used the average of its TLD/film measurement ratios to correct the film to absolute dose. 
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2.5.5 Planar Dose Analysis 
 In the rpcfilm program, the film measurements were compared to the registered treatment 
plan dose distribution. We measured profiles of the dose taken through the center of the primary 
PTV in each orthogonal direction. We took the anterior-posterior and lateral profiles from the axial 
film and the superior-inferior profile from the sagittal films. The film measurements were sampled at 
a 0.3 mm resolution. We smoothed the profiles by using a moving average over eleven data points, 
or 3 mm. We visually compared the film profiles to the treatment plan calculated profiles to 
determine if any major shifts from the planned setup had occurred.  
 The dose fall-off between the posterior edge of the primary PTV and the anterior edge of the 
OAR was evaluated based on DTA. We performed a linear regression of the penumbra on the 
smoothed anterior-posterior profile from the axial film and of the penumbra of the corresponding 
treatment plan profile. We evaluated three points along each linear regression at 25%, 50% and 75% 
of the difference between the maximum and minimum dose levels. The maximum and minimum 
doses were taken as the average of a relatively flat region in the primary PTV and in the OAR, 
respectively. The distance between these doses along the measured and calculated dose profile was 
measured. We calculated the average value of these three distances for each treatment delivery for 
each treatment type and compared it to the RPC acceptability criterion: 4 mm for the penumbra 
between the primary PTV and the OAR. 
 The planar doses measured were also compared to the TPS calculated doses in rpcfilm using 
gamma analysis as described by Low, et al (16). We used this test to evaluate how well our measured 
and calculated dose distributions agree. First, we used acceptability criteria of ±5% dose difference 
and 3 mm DTA with 95% of the points passing being clinically acceptable. These criteria are the 
typical values used by the RPC for IMRT credentialing with anthropomorphic phantoms and are 
common clinical criteria, as well. However, the RPC currently does not include gamma analysis in 
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credentialing for head and neck IMRT. We evaluated an area covering both PTVs and the OAR in 
both the axial and sagittal planes, shown in Figure 2-9 and Figure 2-10, respectively.  
 
 Although the RPC does not use gamma analysis for their head and neck IMRT credentialing, 
they have been collecting data using a ±7% dose difference and 4 mm DTA criteria over a region 
 
Figure 2-9 Area in axial plane where gamma analysis 
was performed with 5% dose difference and 3 mm 
DTA criteria
 
Figure 2-10 Area in sagittal plane where 
gamma analysis was performed with 
5% dose difference and 3 mm DTA 
criteria 
32 
 
 
 
 
defined in the axial plane, shown in Figure 2-11. Therefore, we performed a second gamma analysis 
using ±7% dose difference and 4 mm DTA criteria in a region around the primary PTV in the axial 
plane. We compared the percent of points passing with data collected from 452 institutions that have 
undergone the RPC credentialing process for head and neck IMRT. 
2.5.5.1 Gamma Analysis 
 Gamma analysis is a quantitative evaluation of how well two dose distributions agree (16). It 
incorporates two different criteria to evaluate the agreement of two dose distributions into a single 
value, the  γ-index. The criteria compare points based on the dose difference between the two 
distributions at a point and the distance to a point in the other distribution of the same dose (distance-
to-agreement, DTA). This analysis involves setting the acceptable dose difference and DTA criteria 
and determining how many points are in agreement.  
 The purpose of using two measures to evaluate how well dose distributions agree is to 
provide for high and low dose gradients. In high dose gradients, the dose is changing rapidly from 
point to point, and small spatial errors may cause large differences in dose. However, the distance 
between two points of the same dose may be small. In low dose gradient regions, where the dose is 
 
Figure 2-11 Area in axial plane where 
gamma analysis was performed with 7% 
dose difference and 4 mm DTA criteria 
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more homogenous, small discrepancies in dose value may cause the distance between two points of 
the same dose to be very far away, even if the difference in dose from nearby points is small. 
 The first step in gamma analysis is determining the value of ),( cm rrΓ for every measurement 
and calculation point, which is described by equation 2-5 below, where mr  is a single measurement 
point, and cr  is a spatial point in the calculated dose distribution. mdΔ  is the preset DTA criterion 
and mDΔ  is the preset dose difference criterion. 
2
2
2
2 ),(),(),(
m
cm
m
cm
cm D
rr
d
rrrrr Δ+Δ=Γ
δ
    Eq. 2-5 
where, 
cmcm rrrrr −=),( , the DTA and 
)()(),( mmcccm rDrDrr −=δ , the dose difference 
 ),( cm rrΓ  forms an ellipse when it is set equal to one with the major axes being DTA, 
),( cm rrr , and dose difference, ),( cm rrδ . A ),( cm rrΓ  of less than or equal to one passes the 
acceptance criteria set. The  γ-index is the minimum value of the term, ),( cm rrΓ , for a single 
measurement point, mr . If the γ-index is less than or equal to one, then that point in the measured 
dose distribution passes the acceptance criteria. The γ-index can be found for every point in a 
measured distribution and the total percent of points passing can be determined (16). 
 The software rpcfilm, which we used to perform gamma analyses, has a tool to mask certain 
areas of the film image. This was used to exclude areas beyond the film edge and the pin prick marks 
that were included in the evaluation areas. The mask nullifies the area in the gamma analysis, not 
counting it as passing or failing. 
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2.5.6 MLC Log File Analysis 
 In order to better understand patterns we found in the results, we recorded the dynalog files 
for repeated deliveries of the RapidArc plan. The dynalog files are Varian’s MLC log files and 
record the error in the MLC position, counted every 50 milliseconds, relative to the expected MLC 
position as defined by the treatment plan. The errors are reported in two ways. The first is the root 
mean square (RMS) of the deviation of each leaf over the whole treatment. The other is a histogram 
of the magnitude of the errors of each count. The files were recorded separately for five deliveries of 
each arc and the variation of the RMS leaf deviation was evaluated for the repeated deliveries of the 
RapidArc plan. 
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Chapter 3      Results 
3.1 Treatment Plan Quality Comparison 
 To determine the TPS ability to generate treatment plans that can achieve typical 
prescriptions and constraints for the RPC head and neck phantom, each plan was evaluated on its 
ability to meet the RPC constraints, which were presented in Table 2-2. The results of this analysis 
are shown below in Table 3-1. 
 
 The data in the first row of Table 3-1 defines the prescription for the primary target volume. 
The treatment plans were normalized to meet this objective (6.6 Gy to 95% of the primary PTV 
volume). However, the actual values of primary PTV coverage resulting from the normalization are 
slightly less than 6.60 Gy for 95% of the primary PTV volume. Since this is a result of the treatment 
plan normalization, it was not considered in the analysis of each plan’s ability to comply with the 
RPC dose objectives. All plans passed all of the other dosimetric criteria. 
 Next, we qualitatively compared the DVHs of the three different treatment plans. The DVHs 
are shown in Figure 3-1. The slopes of the DVHs of both PTVs for the Elekta VMAT plans are 
steeper than the other plans, indicating more uniform PTV dose. The RapidArc plan had slightly less 
Table 3-1 The values of each dosimetric objective for all three treatment plans, including 
prescriptions and dose constraints 
Structure Dosimetric Criteria Elekta VMAT RapidArc IMRT 
Primary PTV 
D95% ≥ 6.60 Gy 6.58 Gy 6.60 Gy 6.59 Gy 
D99% ≥ 6.14 Gy 6.37 Gy 6.35 Gy 6.42 Gy 
Secondary PTV 
D95% ≥ 5.40 Gy 5.43 Gy 5.43 Gy 5.41 Gy 
D99% ≥ 5.03 Gy 5.40 Gy 5.28 Gy 5.32 Gy 
Normal tissue max dose ≤ 7.26 Gy 6.76 Gy 6.89 Gy 6.82 Gy 
Organ at risk max dose < 4.5 Gy 4.14 Gy 4.09 Gy 4.10 Gy 
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steep dose than the IMRT plan, as well. However, the normal tissue dose was generally higher for 
the Elekta VMAT plan in comparison to the RapidArc and IMRT plans. 
 The maximum doses in both PTVs, the OAR and the normal tissue were compared to see 
how well the treatment plans could reduce the magnitude of the hot spots. The maximum doses for 
each plan are reported in Table 3-2. The hot spots in the PTVs were lowest for the Elekta VMAT 
plan. The maximum doses of the OAR and normal tissue were similar for all plans. 
 
Figure 3-1 DVHs of the primary PTV (blue), secondary PTV (green), OAR (red), and normal tissue 
(brown) for the Elekta VMAT (solid), RapidArc (dotted), and IMRT (dashed) treatment plans 
Table 3-2 Maximum dose to the primary PTV, secondary PTV, OAR, and normal tissue 
structures with the percent of the prescription dose for each PTV shown in parenthesis 
Structure Elekta VMAT RapidArc IMRT 
Primary PTV 688 cGy (104%) 719 cGy (109%) 714 cGy (108%) 
Secondary PTV 553 cGy (102%) 587 cGy (109%) 581 cGy (108%) 
OAR 4.14 Gy 4.09 Gy 4.10 Gy 
Normal tissue 6.76 Gy 6.89 Gy 6.82 Gy 
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 The percentage of each treatment volume covered by the prescription dose for the secondary 
PTV was determined for all treatment plans. The values obtained for the Elekta VMAT, RapidArc, 
and IMRT plans were 99.2%, 96.0%, and 95.7%, respectively. The Elekta VMAT plan was able to 
achieve greater prescription dose coverage of the secondary PTV. 
 The conformity index (CI) was calculated using equation 2-1 for the primary PTV for all 
treatment plans. Generally, lower values of CI indicate better conformity and a perfectly conformal 
dose would have a CI of 0.95. The resulting CI were 1.08, 1.02, and 1.01 for the Elekta VMAT, 
RapidArc, and IMRT plans respectively. The Elekta VMAT treatment plan had the highest CI, 
indicating that it had a less conformal dose distribution than the RapidArc and IMRT treatment 
plans. This is consistent with the higher normal tissue doses seen in the DVH of the Elekta VMAT 
treatment (brown solid line) in Figure 3-1. 
 The homogeneity index (HI) was calculated using equation 2-2 for both the primary and 
secondary PTVs for all treatment plans. Lower values of HI indicate more uniform dose in the 
treatment volumes. The results are reported in Table 3-3. The RapidArc and IMRT treatment plans 
had the highest HI, indicating that those plans had less uniform dose in the treatment volumes. These 
results are consistent with the DVHs shown in Figure 3-1, where the slopes of the primary and 
secondary PTV DVHs (blue and green solid lines, respectively) are steepest for the Elekta VMAT 
plan. 
 
 Isodose distributions for all three treatment plans can be found in the Appendix in Figure 
5-1, Figure 5-2, Figure 5-3. 
Table 3-3 Homogeneity indices (HI) of both PTVs calculated for all three treatment plans 
Structure Elekta VMAT RapidArc IMRT 
Primary PTV 1.04 1.08 1.07 
Secondary PTV 1.02 1.07 1.06 
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3.2 Dosimetric Accuracy Evaluation 
3.2.1 Absolute Point Dose Analysis 
 The doses at eight locations in the phantom were measured using TLD capsules. All of the 
actual dose values measured are reported in the in Table 3-4 for the Elekta VMAT treatment, Table 
3-5 for the RapidArc treatment, and Table 3-6 for the IMRT treatment. The doses are listed in cGy 
for each TLD measurement for each treatment delivery. The average and percent standard deviation 
of the three deliveries are also shown. Each measurement point is identified by the position of the 
TLD in the phantom. The TLD position is described by the structure the TLD it is located within and 
its placement within that structure (superior versus inferior and, when applicable, anterior versus 
posterior). The greatest percent standard deviation of TLD measurements at a single point for the 
Elekta VMAT, RapidArc, and IMRT treatments were 1.22%, 1.45%, 1.82%, respectively. At most 
measurement locations the percent standard deviation is less than 1% indicating that there is little 
variation in the TLD measurements across treatment deliveries. Table 3-7 shows the mean dose 
calculated for each TLD structure by the TPS for each plan.  
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Table 3-4 Doses measured by eight TLD in the phantom insert for three deliveries of the Elekta VMAT 
treatment 
TLD position Delivery Average Percent standard deviation 1 2 3 
Primary PTV 
Superior Anterior 644 644 647 645 0.27% 
Primary PTV 
Inferior Anterior 643 650 646 646 0.51% 
Primary PTV 
Superior Posterior 635 641 647 641 0.89% 
Primary PTV 
Inferior Posterior 643 641 649 644 0.72% 
Secondary PTV 
Superior 527 534 525 528 0.88% 
Secondary PTV 
Inferior 517 527 529 524 1.22% 
OAR 
Superior 259 261 260 260 0.48% 
OAR 
Interior 253 257 256 256 0.78% 
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Table 3-5 Doses measured by eight TLD in the phantom insert for three deliveries of the RapidArc 
treatment 
TLD position Delivery Average Percent standard deviation 1 2 3 
Primary PTV 
Superior Anterior 724 737 737 732 1.01% 
Primary PTV 
Inferior Anterior 745 742 736 741 0.68% 
Primary PTV 
Superior Posterior 728 734 738 733 0.71% 
Primary PTV 
Inferior Posterior 735 744 751 744 1.08% 
Secondary PTV 
Superior 591 604 608 601 1.45% 
Secondary PTV 
Inferior 621 622 622 622 0.04% 
OAR 
Superior 357 357 358 357 0.06% 
OAR 
Interior 355 361 362 359 1.01% 
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Table 3-6 Doses measured by eight TLD in the phantom insert for three deliveries of the IMRT 
treatment 
TLD position Delivery Average Percent standard deviation 1 2 3 
Primary PTV 
Superior Anterior 704 715 708 709 0.73% 
Primary PTV 
Inferior Anterior 711 704 708 708 0.48% 
Primary PTV 
Superior Posterior 714 713 719 715 0.49% 
Primary PTV 
Inferior Posterior 713 708 714 712 0.41% 
Secondary PTV 
Superior 599 598 590 596 0.89% 
Secondary PTV 
Inferior 599 590 591 593 0.87% 
OAR 
Superior 299 295 306 300 1.82% 
OAR 
Interior 301 293 300 298 1.50% 
42 
 
 
 
 
 
 The ratios of the measured TLD dose to the calculated dose of the corresponding TLD 
structure in the TPS are reported in Table 3-8, Table 3-9, and Table 3-10 for the Elekta VMAT, 
RapidArc, and IMRT treatments, respectively. The six measurement points in the PTVs were 
evaluated to determine if they met the RPC absolute dose criterion of ±7%. The dose of the OAR is 
not included in this analysis since it is generally a steep dose gradient and small errors in position 
may cause larger errors in dose.  
 The ratios at these six locations in the phantom are within 0.93 to 1.07 for all three deliveries 
of all three treatment plans and, therefore, pass the RPC criterion. In the PTVs, where the dose is 
relatively uniform, the IMRT treatment had the best agreement, and the RapidArc treatment had the 
worst agreement. However, in the OAR, where there is a steep dose gradient, the RapidArc treatment 
had the best agreement, and the Elekta VMAT had the worst agreement. Also, the Elekta VMAT 
Table 3-7 Treatment planning system calculation of the mean dose at 
eight TLD locations within the phantom insert 
TLD position Elekta VMAT RapidArc IMRT 
Primary PTV
Superior Anterior 671 694 689 
Primary PTV
Inferior Anterior 671 700 690 
Primary PTV
Superior Posterior 677 697 685 
Primary PTV
Inferior Posterior 681 701 689 
Secondary PTV
Superior 550 575 569 
Secondary PTV
Inferior 551 578 569 
OAR
Superior 321 346 306 
OAR
Interior 317 353 302 
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treatment plans consistently underestimated the dose while the RapidArc and IMRT treatment plans 
mostly overestimated the dose, with the exceptions occurring in the OAR dose. 
 
 
 
 
  
Table 3-8 Ratio of the measured TLD dose to the calculated TPS dose at 
eight locations in the phantom for three deliveries of the Elekta VMAT plan 
TLD position Delivery Average 1 2 3 
Primary PTV
Superior Anterior 0.97 0.97 0.98 0.98 
Primary PTV
Inferior Anterior 0.97 0.98 0.98 0.98 
Primary PTV
Superior Posterior 0.95 0.96 0.97 0.96 
Primary PTV
Inferior Posterior 0.96 0.95 0.97 0.96 
Secondary PTV
Superior 0.97 0.98 0.97 0.98 
Secondary PTV
Inferior 0.95 0.97 0.97 0.97 
OAR
Superior 0.82 0.83 0.82 0.82 
OAR
Interior 0.81 0.82 0.82 0.82 
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Table 3-9 Ratio of the measured TLD dose to the calculated TPS dose at 
eight locations in the phantom for three deliveries of the RapidArc plan 
TLD position Delivery Average 1 2 3 
Primary PTV
Superior Anterior 1.02 1.04 1.04 1.03 
Primary PTV
Inferior Anterior 1.04 1.04 1.03 1.04 
Primary PTV
Superior Posterior 1.02 1.03 1.04 1.03 
Primary PTV
Inferior Posterior 1.03 1.04 1.05 1.04 
Secondary PTV
Superior 1.01 1.03 1.03 1.02 
Secondary PTV
Inferior 1.05 1.05 1.05 1.05 
OAR
Superior 1.01 1.01 1.01 1.01 
OAR
Interior 0.99 1.00 1.00 1.00 
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Table 3-10 Ratio of the measured TLD dose to the calculated TPS dose at 
eight locations in the phantom for three deliveries of the IMRT plan 
TLD position Delivery Average 1 2 3 
Primary PTV
Superior Anterior 1.00 1.02 1.01 1.01 
Primary PTV
Inferior Anterior 1.01 1.00 1.00 1.00 
Primary PTV
Superior Posterior 1.02 1.02 1.03 1.02 
Primary PTV
Inferior Posterior 1.01 1.01 1.01 1.01 
Secondary PTV
Superior 1.03 1.03 1.01 1.02 
Secondary PTV
Inferior 1.03 1.01 1.02 1.02 
OAR
Superior 0.96 0.95 0.98 0.96 
OAR
Interior 0.98 0.95 0.97 0.97 
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3.2.2 Planar Dose Analysis 
3.2.2.1 Dose profile comparison 
 The measured and calculated dose profiles for the Elekta VMAT, RapidArc, and IMRT 
treatments are reported in Figure 3-2 through Figure 3-4 and in the Appendix in Figure 5-4 through 
Figure 5-9. Figure 3-2 through Figure 3-4 show the lateral profiles taken from the axial film through 
the center of the primary PTV. Figure 5-4 through Figure 5-9 show the posterior-to-anterior profile 
measured from the axial film and the inferior-to-superior profile measured from the sagittal films, 
both through the center of the primary PTV. In each figure, the corresponding calculation is shown 
along with the measurements of all three treatment deliveries of each plan. 
 In general, the measured dose profiles were lower than calculation for the Elekta VMAT 
treatment deliveries (Figure 3-2, Figure 5-4, and Figure 5-5), which corresponds with the TLD 
measurements where the ratios of measured to calculated doses was less than one. For the RapidArc 
(Figure 3-3, Figure 5-6, and Figure 5-7) and IMRT treatments (Figure 3-4, Figure 5-8, and Figure 
5-9), the measured dose profiles were greater than calculation. This trend was also seen in the TLD 
measurement to calculation ratios, which were mostly greater than one for both the RapidArc and 
IMRT treatment deliveries. All treatments had difficulty with the posterior-to-anterior dose profile in 
the region of the dose falloff between the primary PTV and the OAR. The Elekta VMAT had the 
greatest deviation between the measured and calculated penumbra in this region (Figure 5-4). This 
corresponds with the large difference between the measured TLD dose in the OAR and calculation 
for the Elekta VMAT treatment, as shown in Table 3-8. The gap in the measurements shown in the 
inferior-to-superior dose profiles (Figure 5-5, Figure 5-7, and Figure 5-9) corresponds to the location 
of the gap between the two sagittal films used to measure these profiles. 
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 The results of the displacement of the measured posterior penumbra from calculation are 
shown in Table 3-11 in millimeters for all treatment deliveries. All deliveries met the 4 mm DTA 
criterion specified by the RPC. The displacement of the penumbra measured from the Elekta VMAT 
treatments is by far the largest, which corresponds with the large deviation seen in the posterior-to-
anterior dose profile measured (Figure 5-4). The displacement of the RapidArc and IMRT treatments 
was no more than 2.0 mm in all cases. 
3.2.2.2 Gamma analysis 
 The agreement of the axial and sagittal film measurements to the corresponding treatment 
plans was evaluated using gamma analysis. The spatial distribution of the gamma analyses’ results 
for all treatments and deliveries are shown in Figure 5-10 through Figure 5-27 in the Appendix, and 
representative examples are shown here in Figure 3-5 through Figure 3-13. The gamma analyses 
shown in these figures did not use the masking feature and, therefore, the entire area, including the 
areas off the film edge, was included in the analyses shown. Consequently, the results of the gamma 
analysis reported in the figures represent artificially lower percent of points passing. 
 The first evaluation used acceptability criteria of ±5% dose difference and 3 mm DTA in 
both the axial and the sagittal planes. The resulting percent of points passing with masking used per 
treatment delivery are reported in Table 3-12. The average percent of points passing for each plane 
evaluated for each treatment technique are shown in the table, as well. The IMRT treatment had the 
highest average percent of points passing (85.7% and 85.4% in the axial and sagittal planes, 
Table 3-11 Displacement (mm) of measurement from calculation of the 
posterior penumbra between the primary PTV and the OAR 
Treatment 
Delivery  
Average 
1 2 3 
Elekta VMAT 3.4 3.5 3.2 3.4 
RapidArc 1.2 1.3 1.7 1.4 
IMRT 2.0 1.9 1.5 1.8 
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respectively) and the Elekta VMAT treatment had the lowest average percent of points passing in the 
axial plane (76.2%) while the RapidArc treatment had the lowest average percent of points passing 
in the sagittal plane (75.4%). We also noted greater variation between deliveries of the Elekta 
VMAT and RapidArc plans than the IMRT plan. The Elekta VMAT results ranged from 70.6% to 
84.0% and the RapidArc results ranged from 68.7% to 84.5%, while the range of percent passing for 
the IMRT treatment was 80.1% to 90.0%. 
 Figure 3-5 through Figure 3-10 show the axial and sagittal film results of one delivery of 
each treatment technique. Most plans failed in regions of sharp dose falloff, such as in the region 
between the primary PTV and the OAR. Some plans also had difficulties meeting the acceptability 
criteria in the high dose regions inside the primary PTV. 
 
Table 3-12 Percent of points passing gamma analysis with acceptability criteria of 
5% dose difference and 3 mm DTA in the axial and sagittal planes bisecting the 
primary PTV 
Treatment Film plane 
Delivery 
Average 
1 2 3 
Elekta VMAT 
axial 70.6% 74.2% 84.0% 76.2% 
sagittal 76.1% 76.6% 79.0% 77.2% 
RapidArc 
axial 84.5% 80.7% 74.8% 80.0% 
sagittal 82.2% 68.7% 75.2% 75.4% 
IMRT 
axial 80.1% 86.9% 90.0% 85.7% 
sagittal 84.4% 88.5% 83.2% 85.4% 
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Figure 3-5 Axial gamma analysis (5%/3mm) of third Elekta VMAT treatment delivery 
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Figure 3-6 Sagittal gamma analysis (5%/3mm) of third Elekta VMAT treatment delivery
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Figure 3-7 Axial gamma analysis (5%/3mm) of first RapidArc treatment delivery 
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Figure 3-8 Sagittal gamma analysis (5%/3mm) of first RapidArc treatment delivery 
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Figure 3-9 Axial gamma analysis (5%/3mm) of second IMRT treatment delivery 
57 
 
 
 
 
 
 
 
 
 
Figure 3-10 Sagittal gamma analysis (5%/3mm) of second IMRT treatment delivery 
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 The second gamma analysis used acceptability criteria of ±7% dose difference and 4 mm 
DTA. The results are reported in Table 3-13. These values were compared with data collected by the 
RPC. As of May 27, 2010, the average percent of points passing gamma analysis was 87% for all 
452 institutions evaluated and 93% for the 365 institutions that were successfully credentialed by the 
RPC (17).  The results of most irradiations of each treatment compare favorably with the national 
average. Only the first delivery of the Elekta VMAT treatment was lower than the national average. 
Only the IMRT treatment had all deliveries performing better than the national average of 
institutions successfully credentialed. 
 For the less stringent acceptability criteria, the percent of points passing the gamma analysis 
improved for all treatment deliveries. The IMRT treatments still had the highest average percent of 
points passing at 96.4%, while the Elekta VMAT and RapidArc had the lowest at 88.4% and 89.9%, 
respectively. The Elekta VMAT treatment still exhibited large variations between deliveries with the 
less stringent acceptability criteria. 
 Representative examples of the spatial distribution of the gamma analyses for one delivery 
of each treatment technique can be seen in Figure 3-11 through Figure 3-13. For the ±7% dose 
difference and 4 mm DTA acceptability criteria, the regions that failed were mostly concentrated in 
the steep dose gradient between the primary PTV and the OAR, with some areas around the 
periphery of the primary PTV still having difficulty. 
Table 3-13 Percent of points passing gamma analysis with 
acceptability criteria of 7% dose difference and 4 mm DTA in 
the axial plane bisecting the primary PTV 
Treatment 
Delivery 
Average 
1 2 3 
Elekta VMAT 83.7% 89.4% 92.1% 88.4% 
RapidArc 91.5% 91.0% 87.3% 89.9% 
IMRT 94.2% 96.9% 98.0% 96.4% 
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Figure 3-11 Axial gamma analysis (7%/4mm) of third Elekta VMAT treatment delivery 
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Figure 3-12 Axial gamma analysis (7%/4mm) of first RapidArc treatment delivery 
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Figure 3-13 Axial gamma analysis (7%/4mm) of third IMRT treatment delivery 
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3.2.3 MLC Log File Analysis 
 The MLC dynalog files for repeated RapidArc deliveries were analyzed to explore the 
variation in the gamma analysis results across five treatment deliveries of the same plan. Table 3-14 
and Table 3-15 show the minimum, maximum, and range of the RMS values of each moving leaf for 
the five treatment deliveries. Table 3-14 shows the results of the first, clockwise arc, and Table 3-15 
shows the second, counterclockwise arc. Only the results of the moving leaves are shown, which 
included the central sixteen leaves. The RMS values of leaf deviation for the peripheral leaves were 
zero. The results of each carriage are shown separately. 
 
Table 3-14 The minimum, maximum, and range of the RMS values of leaf deviation (cm) 
for each moving leaf of both carriages for five deliveries of the first, clockwise arc of the 
RapidArc treatment 
  Carriage A Carriage B 
Leaf Minimum Maximum Range Minimum Maximum Range 
23 0.026 0.027 0.001 0.024 0.024 0 
24 0.043 0.044 0.001 0.041 0.041 0 
25 0.051 0.051 0 0.038 0.038 0 
26 0.043 0.043 0 0.041 0.041 0 
27 0.046 0.047 0.001 0.043 0.044 0.001 
28 0.044 0.044 0 0.037 0.037 0 
29 0.043 0.044 0.001 0.038 0.038 0 
30 0.043 0.043 0 0.046 0.046 0 
31 0.046 0.046 0 0.051 0.051 0 
32 0.036 0.037 0.001 0.044 0.045 0.001 
33 0.035 0.035 0 0.04 0.041 0.001 
34 0.038 0.038 0 0.047 0.048 0.001 
35 0.04 0.041 0.001 0.052 0.052 0 
36 0.031 0.031 0 0.045 0.045 0 
37 0.031 0.031 0 0.043 0.043 0 
38 0.023 0.024 0.001 0.023 0.024 0.001 
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 The RMS values of the individual leaf variation remained mostly constant across all 
deliveries. The RMS leaf deviation varied at most 0.01 mm across all deliveries. The RMS values of 
leaf deviation for the moving leaves for each treatment delivery are shown in the Appendix in Table 
5-1 and Table 5-2. 
 
 
 
 
Table 3-15 The minimum, maximum, and range of the RMS values of leaf deviation (cm) 
for each moving leaf of both carriages for five deliveries of the second, counterclockwise 
arc of the RapidArc treatment 
  Carriage A Carriage B 
Leaf Minimum Maximum Range Minimum Maximum Range 
23 0.021 0.022 0.001 0.024 0.024 0 
24 0.036 0.037 0.001 0.051 0.051 0 
25 0.035 0.035 0 0.044 0.044 0 
26 0.041 0.041 0 0.051 0.051 0 
27 0.048 0.048 0 0.051 0.051 0 
28 0.043 0.043 0 0.052 0.052 0 
29 0.049 0.049 0 0.056 0.057 0.001 
30 0.043 0.043 0 0.047 0.048 0.001 
31 0.049 0.049 0 0.04 0.04 0 
32 0.044 0.044 0 0.048 0.049 0.001 
33 0.046 0.046 0 0.04 0.041 0.001 
34 0.051 0.051 0 0.031 0.032 0.001 
35 0.046 0.046 0 0.034 0.034 0 
36 0.047 0.047 0 0.032 0.032 0 
37 0.041 0.042 0.001 0.03 0.031 0.001 
38 0.028 0.028 0 0.026 0.027 0.001 
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Chapter 4      Discussion 
4.1 General Discussion 
 Our results indicate that the two VMAT techniques evaluated in this study have the ability to 
generate plans of comparable quality as IMRT while delivering the calculated dose distributions 
within acceptable tolerances for complex treatments, such as head and neck radiotherapy. Clinics 
may chose to use these VMAT techniques in lieu of IMRT for various treatment sites in order to 
reduce the total time of treatment for the patient and potentially reduce the MU necessary for some 
treatment sites (4-7). However, each clinic should make treatment decisions based on their specific 
requirements and should perform their own thorough QA of whichever treatment technique they 
choose. Also, because of the differences in the TPS, thorough treatment planning studies should be 
conducted to determine what treatment is best for their specific clinic and even for specific patient 
cases. 
 In treatment planning studies, it is important to remember that they are not entirely objective. 
The results are influenced by several factors, including the abilities of the person planning 
treatments, the techniques used, the treatment site and geometry, and the time spent on a plan. As a 
result, plans of varying quality can be generated for the same patient using the same treatment 
planning system. These subjectivities of treatment planning confound the investigation of TPS 
performance. 
 Although treatment planning studies are partially subjective, the treatment planning 
differences in conformity and uniformity seen between the plans may be attributed to the planning 
objectives available in each TPS. In Pinnacle3, where the dose distribution was more uniform in the 
treatment volumes, the target dose objectives can be set to achieve uniform dose at a specified 
prescription. In Eclipse, there is no uniform dose objective, just a minimum dose objective. In order 
to increase the uniformity of the target dose, a maximum dose objective can be specified. Eclipse 
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also has a normal tissue objective which attempts to improve the dose falloff from the target volume, 
but Pinnacle3 does not. These differences in dose objective specification may explain the tradeoff 
between uniformity and conformity in the treatment plans produced by Pinnacle3 and Eclipse, 
respectively; however, this needs to be verified through further testing. 
 As for the dosimetric accuracy results, the measured doses delivered by the Elekta VMAT 
and RapidArc techniques were consistent with the calculated doses, however the IMRT 
measurements corresponded to their calculation better overall. The DTA agreement of the posterior 
penumbra of the primary PTV as measured from the film was greater for the Elekta VMAT 
treatment. Also, the percent of points passing the gamma analysis was lower for both the Elekta 
VMAT and RapidArc treatments. Additionally, there appeared to be greater variation between 
treatments in the results of the gamma analyses at the ±5% dose difference and 3 mm DTA level. 
The simultaneous gantry rotation with varying speeds and dynamic MLC motion may be the cause of 
the reduced agreement. Although the MLC deviations did not seem to vary between treatments, the 
additional uncertainty of the gantry position, gantry rotation speed and MLC positions are 
compounded in VMAT treatments and could be the cause of the differences in the dose delivery 
from treatment to treatment. The plans evaluated in this study involved a high degree of modulation, 
which may have caused the linacs to utilize more MLC motion and gantry rotation speed variation 
than plans with less modulation. The effects of these complex motions and their uncertainties need to 
be fully understood for QA and should be further investigated. 
 The literature, for the most part, is in agreement with the findings of these studies. Several 
planning studies have been conducted for VMAT techniques utilizing two arcs and found that they 
were equivalent to IMRT. One study by Rao, et al. has found that Elekta VMAT planned with 
Pinnacle3 SmartArc generated plans that were comparable in target coverage and critical structure 
sparing to IMRT for six prostate and six head and neck patient cases (7). A study by Verbakel, et al. 
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has concluded that RapidArc was similar to seven field sliding window IMRT for twelve head and 
neck treatments that, like our study, had a primary and secondary PTV prescription (6). They found 
that the sparing of the OAR was similar, but that the RapidArc plans were significantly less 
conformal. In their study, they used an older version of Eclipse that could not simultaneously 
optimize two arcs, which could explain why our results found consistent conformality between 
RapidArc and IMRT. 
One study found that RapidArc performed better than both five and nine field sliding 
window IMRT (4). In this study by Oliver, et al. that investigated virtual phantoms of varying 
geometries, they found that the RapidArc plans had better conformity and uniformity and were better 
able to meet the dose objectives than the IMRT plans. As mentioned before, planning studies are 
subjective and this could explain the different findings. 
As for dosimetric accuracy, the literature has found consistently that the accuracy of VMAT 
treatments is clinically acceptable. In studies of Elekta VMAT, it was found in two separate studies 
that greater than 95% of points passed gamma analysis with criteria of 3% dose difference and 3 mm 
DTA (5, 7). The study by Bedford and Warrington investigated prostate and lung plans using a diode 
array. However, they planned their treatment using in-house TPS and transferred the plans to be 
calculated in Pinnacle3 (5). Rao, et al. evaluated prostate and head and neck cases with a two-
dimensional ion chamber array and, similarly to this study, planned their treatments with Pinnacle3 
SmartArc (7). 
RapidArc accuracy was evaluated in a Monte Carlo study by Gagne, et al. and found to be 
adequate for clinical use when a 2.5 mm grid was used to calculate dose in Eclipse (8). Two 
additional studies used measurement to verify RapidArc delivery (6, 9). In one, Korreman, et al. 
found that greater than 95% of points passed 3% dose difference and 3 mm DTA criteria when 
prostate and head and neck treatments were measured with a diode array calibrated to an ion 
chamber (9). The other study by Verbakel, et al. used EBT films to measure the dose of a head and 
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neck plan in several coronal planes and found that greater than 99% of the points passed a gamma 
analysis with 3% dose difference and 2 mm DTA criteria (6). In fact, both of these studies found that 
RapidArc performed better than IMRT. 
The literature agrees with the conclusions of this study that the accuracy of VMAT 
techniques is acceptable. However, each study using gamma analysis has found a higher percent of 
points passing for stricter criteria (3% dose difference and 3 mm DTA or less). Also, some studies 
found, upon comparison with IMRT, that RapidArc performed better. There may be several 
explanations for this discrepancy. The simplest is that plans that are more challenging may affect the 
accuracy of treatment techniques differently. For example, in order to deliver the degree of 
modulation of dose necessary for more complex plans, VMAT treatments may need to utilize more 
gantry rotation speed variation. This variation may add additional uncertainty to the treatment. An 
IMRT plan would only need to increase the MU and number of segments at a static gantry angle. 
Furthermore, the actual behavior of the linac rotation may vary from what the TPS expects in order 
to deliver the plan. The plans in this study were very complex with a high degree of modulation and 
may yield different results for different treatment techniques. 
Other reasons for the discrepancy may involve the technique of measurement. For studies 
involving an ion chamber or diode array, the spatial resolution is limited (5, 7, 9). In order to perform 
a gamma analysis, they must interpolate between measurement points, which can affect the results. 
For example, two studies used the Delta4 phantom, which has a spatial resolution of 5 mm in the 
central 6 cm by 6 cm area and 10 mm at the periphery (5, 9). 
In another example, the ion chamber array used in the study by Rao, et al. had a spatial 
resolution of 7.6 mm and measurements were linearly interpolated to 1 mm spatial resolution. 
Measurements in this study were analyzing at a 3 mm DTA criterion. They noted that film 
measurements would be able to detect a greater degree of modulation (7). Ion chamber arrays have a 
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volume averaging affect that can smooth the measurements, as well. The volume of the chamber in 
the MatriXX array used in this study was 0.08 cm3 (7).  
Our analysis used EBT2 film that was not smoothed before performing the gamma analysis. 
The inherent noise of these measurements may have affected the accuracy. Also, this technique has a 
much higher spatial resolution and does not need to interpolate measurements. Therefore, it can 
detect greater dose modulation. 
The normalization technique used in each study may also affect the accuracy found. Many 
studies do not mention how they calibrate or normalize their measurements. Film is known to be a 
less accurate method of dosimetry and is often used for relative dose accuracy evaluation. In this 
study, we normalized our film measurements to TLD measurements, following RPC protocol. 
Absolute measurements, like ours, are more strenuous. In the study by Verbakel, et al., they used two 
pieces of EBT film in each measurement plane. This technique can be used to reduce the uncertainty 
of inhomogenous film construction (18). However, they did not mention their normalization 
technique, nor if they smoothed their film before comparing it to the treatment plan (6). For these 
reasons, it makes it difficult to compare the results of different QA measurement techniques. 
 Our study followed the RPC protocol to determine if the plans were delivered within 
acceptable accuracy tolerances. This well established protocol assesses absolute dose measurements 
and has been used for years to evaluate institutions internationally. Additionally, it evaluates the 
VMAT techniques in an extreme situation. The plans evaluated were very complex with steep dose 
gradients and multiple target volumes with different prescriptions. Also, it was the first study to 
compare different VMAT techniques head to head and offered new insight in how they perform in 
similar situations. The VMAT techniques we chose to evaluate involved linacs, the Varian Clinac iX 
and Elekta Synergy, and TPS, Pinnacle3 and Eclipse, that are established and prevalent in the US. 
 Although this study has many strengths, there are a few limitations. The plans were 
generated for a phantom simulating real head and neck geometry. However, human anatomy is more 
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complex and diverse. This study has shown that VMAT techniques can develop plans of IMRT 
quality, but they may not always do so in all patient cases. Additionally, this was only a planning 
study and cannot fully predict patient outcomes. Prospective clinical trials are needed to determine if 
the effects of treatments are actually the same when VMAT is used in place of IMRT. 
 Overall, this study has contributed to the body of knowledge on the treatment planning 
capabilities of two VMAT techniques and, for the first time, has compared them. Clinicians now 
have more information to decide if VMAT is an appropriate treatment for their patients. It may be 
used to help reduce the discomfort of long treatment times and help increase throughput in a clinic 
(4-7). Additionally, it assures them that the treatments can be delivered with acceptable accuracy. 
 
4.2 Conclusion 
 In conclusion, our hypothesis that the VMAT techniques evaluated would generate plans of 
comparable quality to IMRT and accurately deliver the calculated dose for complex head and neck 
treatments was supported by the results. All treatment plans performed similarly across all metrics 
used to evaluate treatment plan quality with the exception of a tradeoff between dose conformity to 
and uniformity in the treatment volumes. The Elekta VMAT treatment, planned with Pinnacle3 Smart 
Arc, had more uniform target dose but less conformal plans than the RapidArc and IMRT treatments, 
planned with Eclipse. Additionally, all deliveries of all treatments passed the RPC credentialing 
criteria. When compared to the average percent of points passing gamma analysis for all institutions 
passing head and neck IMRT credentialing, the three treatment techniques evaluated compared 
favorably on average. 
 
4.3 Future Work 
 There are many questions left about the clinical impact of VMAT treatments. The shorter 
treatment times, greater spreading of lower doses, and potentially fewer MU involved with VMAT 
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may have radiobiological and clinical effects. These should be studied for their effects on cell kill, 
tumor control, patient morbidity, late effects, and overall survival. 
 The complicated combination of the variable gantry rotation speed and dynamic MLC 
motion should be further investigated to fully understand their uncertainties. Similarly, the ability of 
the TPS to predict the gantry motion should be examined to potentially improve the dose calculation 
accuracy. 
 Lastly, there are several VMAT products available, including linacs capable of delivering 
VMAT treatments and TPS for VMAT planning and dose calculation, and some can be used with 
multiple vendors. Many combinations of these products should be investigated to encompass the full 
range of systems available. 
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Chapter 5      Appendix 
5.1 Treatment Plan Isodose Distributions 
 
 
 
 
Figure 5-1 Isodose distribution of the Elekta VMAT treatment plan 
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Figure 5-2 Isodose distribution of the RapidArc treatment plan 
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Figure 5-3 Isodose distribution of the IMRT treatment plan 
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5.2 Dose profiles 
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5.3 Gamma analysis 
 
 
Figure 5-10 Axial gamma analysis (5%/3mm) of first Elekta VMAT treatment delivery 
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Figure 5-11 Sagittal gamma analysis (5%/3mm) of first Elekta VMAT treatment delivery 
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Figure 5-12 Axial gamma analysis (5%/3mm) of second Elekta VMAT treatment delivery 
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Figure 5-13 Sagittal gamma analysis (5%/3mm) of second Elekta VMAT treatment delivery
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Figure 5-14 Axial gamma analysis (5%/3mm) of second RapidArc treatment delivery 
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Figure 5-15 Sagittal gamma analysis (5%/3mm) of second RapidArc treatment delivery 
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Figure 5-16 Axial gamma analysis (5%/3mm) of third RapidArc treatment delivery 
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Figure 5-17 Sagittal gamma analysis (5%/3mm) of third RapidArc treatment delivery 
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Figure 5-18 Axial gamma analysis (5%/3mm) of first IMRT treatment delivery 
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Figure 5-19 Sagittal gamma analysis (5%/3mm) of first IMRT treatment delivery 
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Figure 5-20 Axial gamma analysis (5%/3mm) of third IMRT treatment delivery 
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Figure 5-21 Sagittal gamma analysis (5%/3mm) of third IMRT treatment delivery
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Figure 5-22 Axial gamma analysis (7%/4mm) of first Elekta VMAT treatment delivery
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Figure 5-23 Axial gamma analysis (7%/4mm) of second Elekta VMAT treatment delivery
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Figure 5-24 Axial gamma analysis (7%/4mm) of second RapidArc treatment delivery
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Figure 5-25 Axial gamma analysis (7%/4mm) of third RapidArc treatment delivery
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Figure 5-26 Axial gamma analysis (7%/4mm) of first IMRT treatment delivery 
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Figure 5-27 Axial gamma analysis (7%/4mm) of second IMRT treatment delivery 
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5.4 MLC Log File Results 
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